Abstract
Traditionally, the development of drugs has focused on small molecule therapeutics. However, with recent advances in recombinant protein technology the potential of proteins as therapeutics is starting to be realized. Already there are protein drugs on the market, including naturally occurring proteins, engineered proteins and proteins introduced into the patient by way of gene therapy. The next generation of such drugs are likely to be designed molecules, proteins devised from scratch and specifically tailored to have a required 3-dimensional structure and biochemical function. The key to such de novo design is the extensive bioinformatics knowledge that has been obtained from experimentally determined protein structures during the past 40-50 years. The knowledge is far from complete, for example, the protein folding problem has not yet been completely solved. Despite this, bioinformatics plays a crucial role in protein design, as is outlined in this review, and a number of de novo protein structures have been successfully designed in recent years. Some examples of these successes, which are available in the Protein Data Bank, are presented. They suggest that carefully designed protein therapeutics are a genuine prospect for the future.
Keywords: Bioinformatics, Protein Design
Current Pharmaceutical Biotechnology
Title: Bioinformatics and Protein Design
Volume: 3 Issue: 4
Author(s): Roman A. Laskowski and A.W. Edith Chan
Affiliation:
Keywords: Bioinformatics, Protein Design
Abstract: Traditionally, the development of drugs has focused on small molecule therapeutics. However, with recent advances in recombinant protein technology the potential of proteins as therapeutics is starting to be realized. Already there are protein drugs on the market, including naturally occurring proteins, engineered proteins and proteins introduced into the patient by way of gene therapy. The next generation of such drugs are likely to be designed molecules, proteins devised from scratch and specifically tailored to have a required 3-dimensional structure and biochemical function. The key to such de novo design is the extensive bioinformatics knowledge that has been obtained from experimentally determined protein structures during the past 40-50 years. The knowledge is far from complete, for example, the protein folding problem has not yet been completely solved. Despite this, bioinformatics plays a crucial role in protein design, as is outlined in this review, and a number of de novo protein structures have been successfully designed in recent years. Some examples of these successes, which are available in the Protein Data Bank, are presented. They suggest that carefully designed protein therapeutics are a genuine prospect for the future.
Export Options
About this article
Cite this article as:
Laskowski A. Roman and Chan Edith A.W., Bioinformatics and Protein Design, Current Pharmaceutical Biotechnology 2002; 3 (4) . https://dx.doi.org/10.2174/1389201023378157
DOI https://dx.doi.org/10.2174/1389201023378157 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Screening of Early and Late Onset Alzheimer’s Disease Genetic Risk Factors in a Cohort of Dementia Patients from Liguria, Italy
Current Alzheimer Research Updating the Chemistry and Biology of Cannabinoid CB2 Receptor – Specific Inverse Agonists
Current Topics in Medicinal Chemistry Biological Mechanisms Linking Alzheimer's Disease and Type-2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Molecular Biomarkers for Amyotrophic Lateral Sclerosis
Current Bioinformatics Functional Roles of Benzothiazole Motif in Antiepileptic Drug Research
Mini-Reviews in Medicinal Chemistry Vascular Endothelial Growth Factor in Central Nervous System Injuries – A Vascular Growth Factor Getting Nervous?
Current Neurovascular Research Induced Adaptive Resistance to Nitrooxidative Stress in the CNS: Therapeutic Implications
Central Nervous System Agents in Medicinal Chemistry Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Current Neuropharmacology Neuroprotection with Natural Antioxidants and Nutraceuticals in the Context of Brain Cell Degeneration: The Epigenetic Connection
Current Topics in Medicinal Chemistry The Role of Autophagy in the Pathogenesis of Ischemic Stroke
Current Neuropharmacology Editorial (Hot Topic: Targeting Histone Acetylation for Neuroprotection)
Current Pharmaceutical Design Delivering RNA Interference to the Mammalian Brain
Current Gene Therapy Antioxidant Properties of Crocus Sativus L. and Its Constituents and Relevance to Neurodegenerative Diseases; Focus on Alzheimer’s and Parkinson’s Disease
Current Neuropharmacology Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA)
Current Neuropharmacology New Hope for the Diagnosis and Therapy of Alzheimers Disease
Protein & Peptide Letters Immunosuppressive Properties of Mesenchymal Stem Cells: Advances and Applications
Current Molecular Medicine The Neuroprotective Role of PEDF: Implication for the Therapy of Neurological Disorders
Current Molecular Medicine Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?
Current Neuropharmacology Signaling Mechanisms Underlying Aβ Toxicity: Potential Therapeutic Targets for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Protein Misfolding and Aggregation in Alzheimer's Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets